-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEAYA BIOSCIENCES COMPLETES TARGETED FULL ENROLLMENT IN RANDOMIZED PIVOTAL PHASE 2/3 TRIAL (OPTIMUM-02) OF DAROVASERTIB IN COMBINATION WITH CRIZOTINIB IN FIRST-LINE HLA*A2-NEGATIVE METASTATIC UVEAL MELANOMA

路透·12/11/2025 11:00:00

登錄查看新聞詳情